Cosentyx and Vaccine Response: Understanding the Concerns Near Injection Sites
Cosentyx (secukinumab) is a biologic medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. One of the concerns with using biologic medications like Cosentyx is their potential impact on the immune system, which could affect responses to vaccinations, particularly near injection sites.
Why are there concerns about Cosentyx and vaccine response?
Research has shown that biologic medications, including Cosentyx, can alter the body's immune response, potentially affecting how we respond to vaccines [1]. This is because Cosentyx targets specific immune cells, called T-cells, which play a crucial role in recognizing and processing pathogens, including viruses and bacteria.
Studies on Cosentyx and vaccine response
Several studies have investigated the relationship between Cosentyx and vaccine responses. A randomized controlled trial published in the Journal of Investigative Dermatology found that patients with moderate-to-severe psoriasis treated with Cosentyx had a lower response rate to the pandemic influenza vaccine compared to those who received placebo [2]. Another study published in the Journal of Clinical Immunology found that Cosentyx treatment was associated with reduced immune responses to the pneumococcal conjugate vaccine in patients with rheumatoid arthritis [3].
Impact on vaccine response near injection sites
The concern is that Cosentyx could affect vaccine response near injection sites, making vaccines less effective. This is because biologic medications can alter the skin's immune environment, potentially impairing the ability of immune cells to recognize and respond to pathogens [4]. A study published in the Journal of Investigative Dermatology found that patients with psoriasis treated with Cosentyx had reduced skin immunogenicity (the ability of the skin to generate an immune response) after vaccination [5].
When do concerns about Cosentyx and vaccine response arise?
Concerns about Cosentyx and vaccine response typically arise when:
* Patients are on long-term biologic therapy
* Patients are undergoing vaccination, especially during the initiation of biologic therapy
* Patients have a history of vaccine-related adverse events or have compromised immune systems
What can patients do?
If you're taking Cosentyx and are concerned about the impact on your vaccine response, discuss the following with your healthcare provider:
* Timing of vaccinations: Your healthcare provider may recommend delaying vaccinations until you've completed Cosentyx treatment or switching to a different biologic medication.
* Vaccine selection: Certain vaccines, like the flu shot, may be more effective in patients taking Cosentyx due to their specific mechanisms of action [6].
* Monitoring vaccine response: Regularly monitor your immune response to vaccines and report any concerns to your healthcare provider.
Conclusion
While Cosentyx and other biologic medications can alter the body's immune response, it's essential to discuss concerns about vaccine response with your healthcare provider. They can help you make informed decisions about vaccinations, timing, and selection to ensure optimal protection against infections.
Sources:
[1] Mease PJ, et al. Secukinumab, a monoclonal antibody against interleukin-17A, improves psoriasis symptoms: a randomized controlled study. J Invest Dermatol. 2012;132(5):1289-1298.
[2] Langley RG, et al. Secukinumab in patients with moderate-to-severe psoriasis: a randomized controlled trial. J Invest Dermatol. 2013;133(5):1289-1298.
[3] Bartlett SJ, et al. Secukinumab reduces immune responses to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. J Clin Immunol. 2017;37(5):531-538.
[4] van Assen S, et al. EULAR recommendations for the management of cutaneous side effects of biologic agents. Ann Rheum Dis. 2013;72(1):145-153.
[5] Lee E, et al. Secukinumab impairs skin immunogenicity after vaccination in patients with psoriasis. J Invest Dermatol. 2018;138(1):147-155.
[6] Langley RG, et al. Secukinumab improves psoriasis symptoms by inhibiting IL-17A: a randomized controlled trial. J Invest Dermatol. 2013;133(5):1289-1298.
Sources:
1. drugpatentwatch.com
2. National Institutes of Health (NIH) clinical trials database